Home/Filings/3/0000899243-18-027747
3//SEC Filing

Andera Partners 3

Accession 0000899243-18-027747

CIK 0001603756other

Filed

Oct 29, 8:00 PM ET

Accepted

Oct 30, 9:32 PM ET

Size

12.6 KB

Accession

0000899243-18-027747

Insider Transaction Report

Form 3
Period: 2018-10-30
Holdings
  • Series B-1 Preferred Stock

    (indirect: See footnote)
    Common Stock (806,080 underlying)
  • Series C Preferred Stock

    (indirect: See footnote)
    Common Stock (654,237 underlying)
  • Series A Preferred Stock

    (indirect: See footnote)
    Common Stock (799,228 underlying)
  • Series B-2 Preferred Stock

    (indirect: See footnote)
    Common Stock (431,250 underlying)
Holdings
  • Series A Preferred Stock

    (indirect: See footnote)
    Common Stock (799,228 underlying)
  • Series C Preferred Stock

    (indirect: See footnote)
    Common Stock (654,237 underlying)
  • Series B-1 Preferred Stock

    (indirect: See footnote)
    Common Stock (806,080 underlying)
  • Series B-2 Preferred Stock

    (indirect: See footnote)
    Common Stock (431,250 underlying)
Footnotes (6)
  • [F1]Each share of Series A preferred stock is convertible, at any time, at the reporting person's election, into shares of the Issuer's common stock at the then-effective conversion rate for no additional consideration in accordance with the Issuer's Fourth Amended and Restated Certificate of Incorporation, as amended to date. In addition, effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of the Series A preferred stock will automatically convert into 2.31660 shares of the Issuer's common stock. The Series A preferred stock has no expiration date.
  • [F2]Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018.
  • [F3]This report is filed jointly by Andera Partners ("Andera") and BioDiscovery 4 FCPR ("BioDiscovery"). The shares are held of record by BioDiscovery. Andera is the manager of BioDiscovery and may be deemed to have sole voting and dispositive power over the shares held by BioDiscovery.
  • [F4]Each share of Series B-1 preferred stock is convertible, at any time, at the reporting person's election, into shares of the Issuer's common stock at the then-effective conversion rate for no additional consideration in accordance with the Issuer's Fourth Amended and Restated Certificate of Incorporation, as amended to date. In addition, effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of the Series B-1 preferred stock will automatically convert into 1.2 shares of the Issuer's common stock. The Series B-1 preferred stock has no expiration date.
  • [F5]Each share of Series B-2 preferred stock is convertible, at any time, at the reporting person's election, into shares of the Issuer's common stock at the then-effective conversion rate for no additional consideration in accordance with the Issuer's Fourth Amended and Restated Certificate of Incorporation, as amended to date. In addition, effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of the Series B-2 preferred stock will automatically convert into 1.2 shares of the Issuer's common stock. The Series B-2 preferred stock has no expiration date.
  • [F6]Each share of Series C preferred stock is convertible, at any time, at the reporting person's election, into shares of the Issuer's common stock at the then-effective conversion rate for no additional consideration in accordance with the Issuer's Fourth Amended and Restated Certificate of Incorporation, as amended to date. In addition, effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of the Series C preferred stock will automatically convert into 1.2 shares of the Issuer's common stock. The Series C preferred stock has no expiration date.

Issuer

Axonics Modulation Technologies, Inc.

CIK 0001603756

Entity typeother
IncorporatedFrance

Related Parties

1
  • filerCIK 0001757283

Filing Metadata

Form type
3
Filed
Oct 29, 8:00 PM ET
Accepted
Oct 30, 9:32 PM ET
Size
12.6 KB